Drug Trial Radar · NCT03547167
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
Last checked: Nov 19, 2026Latest source record: Jan 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,515
Actual
Start
Jul 16, 2018
Primary completion
Jan 20, 2020
Study completion Jan 20, 2020
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13™ in pneumococcal vaccine-naïve adults at increased risk for pneumococcal disease and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX™23 when administered 6 months after receipt of either V114 or Prevnar 13™. Increased risk for pneumococcal disease is defined as 1) an underlying medical condition, 2) behavioral habits such as smoking or alcohol use, or 3) living in a community/environment with increased risk of disease transmission.
Conditions
- Pneumococcal Infections
Interventions
V114Biological
15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
Prevnar 13™Biological
13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
PNEUMOVAX™23Biological
23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™Time frame: Up to 5 days after Vaccination 1
- Percentage of Participants With Solicited Systemic Adverse Events Following V114 or Prevnar 13™Time frame: Up to 14 days after Vaccination 1
- Percentage of Participants With a Vaccine-related Serious Adverse Event Following V114 or Prevnar 13™Time frame: Up to Month 6 (before Vaccination 2)
- Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity Day 30 Following V114 or Prevnar 13™Time frame: Day 30
Locations
78 sites in 7 countries. Site status is shown where the registry gives one.
Chinle Comprehensive Health Care Facility ( Site 0001)
Chinle, Arizona
Fort Defiance Center for American Indian Health ( Site 0002)
Fort Defiance, Arizona
Pulmonary Associates, PA ( Site 0043)
Glendale, Arizona
Central Phoenix Medical Clinic, LLC ( Site 0031)
Phoenix, Arizona
Whiteriver Center for American Indian Health ( Site 0005)
Whiteriver, Arizona
Inland Empire Clinical Trials, LLC ( Site 0052)
Rialto, California
Top Medical Research, Inc ( Site 0033)
Cutler Bay, Florida
Indago Research & Health Center, Inc ( Site 0054)
Hialeah, Florida
Renstar Medical Research ( Site 0008)
Ocala, Florida
Triple O Research Institute, P.A. ( Site 0026)
West Palm Beach, Florida
Emory University School of Medicine at Grady Hospital ( Site 0027)
Atlanta, Georgia
Kootenai Health ( Site 0042)
Coeur d'Alene, Idaho
Evanston Premier Healthcare & Research, LLC. ( Site 0012)
Evanston, Illinois
Pharmakon Inc ( Site 0049)
Evergreen Park, Illinois
Reid Physician Associates ( Site 0055)
Richmond, Indiana
The Center for Pharmaceutical Research PC ( Site 0050)
Kansas City, Missouri
Clinical Research Consortium ( Site 0053)
Las Vegas, Nevada
Internal Medicine Associates [Bridgeton, NJ] ( Site 0015)
Bridgeton, New Jersey
Gallup Center for American Indian Health ( Site 0003)
Gallup, New Mexico
Shiprock Center for American Indian Health ( Site 0004)
Shiprock, New Mexico
Corning Center For Clinical Research ( Site 0036)
Corning, New York
Mid Hudson Medical Research ( Site 0022)
New Windsor, New York
Wake Research Associates, LLC ( Site 0016)
Raleigh, North Carolina
Lehigh Valley Health Network ( Site 0040)
Allentown, Pennsylvania
University of Pennsylvania ( Site 0030)
Philadelphia, Pennsylvania
Mountain View Clinical Research ( Site 0007)
Greer, South Carolina
Holston Medical Group ( Site 0025)
Kingsport, Tennessee
AIM Trials ( Site 0060)
Fort Worth, Texas
University of Texas Medical Branch at Galveston ( Site 0034)
Galveston, Texas
Private Practice Leadership, LLC ( Site 0051)
Houston, Texas
Texas Center For Drug Development ( Site 0041)
Houston, Texas
Texas Institute Of Cardiology ( Site 0048)
McKinney, Texas
Village Health Partners ( Site 0006)
Plano, Texas
Copperview Medical Center ( Site 0038)
South Jordan, Utah
Timber Lane Allergy & Asthma Research, LLC ( Site 0044)
South Burlington, Vermont
Pulmonary & Sleep Research ( Site 0046)
Spokane Valley, Washington
Gundersen Health System ( Site 0021)
La Crosse, Wisconsin
Marshfield Clinic ( Site 0013)
Marshfield, Wisconsin
Paratus Clinical Kanwal ( Site 0172)
Kanwal, Australia
Nepean Hospital ( Site 0176)
Kingswood, Australia
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.